Roche Lifts Forecast as New Drugs Take Over to Drive Growth
- New breast cancer drug helps profit exceed analyst estimates
- Next generation of owning families to seek board seat in 2020
This article is for subscribers only.
Roche Holding AG raised this year’s profit and sales forecast as new medicines made up for eroding sales of its biggest drugs, which face competition from cheaper copies.
Sales will probably rise by a mid-single-digit percentage, boosted by U.S. tax reductions, the Basel, Switzerland-based company said in a statement Thursday. That will lift profit further after first-half results blew past analyst expectations.